Tenax Therapeutics TENX 深 沪
等待开盘 08-20 09:30:00 美东时间
1.90
+0.200
+11.76%
华盛通- 最 高1.96
- 今 开1.75
- 成交量 1193.04万股
- 最 低 1.70
- 昨 收 1.70
- 总市值 7110.54万
- 52周最高 19.40
- 市盈率 静 --
- 换手率 31.88%
- 52周最低 1.31
- 委 比 -91.11%
- 总股本 3742.39万
- 历史最高 274560.00
- 量 比 1.14
- 振 幅 15.29%
- 历史最低 1.31
- 每 手 1
- 风险率 3.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
08-12 00:02
Tenax Therapeutics Reports Phase 3 LEVEL Trial Of TNX‑103 In PH‑HFpEF; Study Did Not Meet Primary Or Key Secondary Endpoints
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 resulted in a 49% greater reduction in NT-proBNP compared to placebo (nominal p<0...
08-10 19:07
Tenax Therapeutics Q2 EPS $(0.35) Beats $(0.37) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 29.63 percent decrease over losses of $(0.27) per share from the same period last year.
07-31 19:30
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Tenax Therapeutics reported Q2 2026 financial results with $118M cash, increased R&D expenses to $12.9M, and a net loss of $17.8M. The company expects Phase 3 LEVEL trial top-line data in August 2026 and plans to present results at the ESC Congress. Enrollment for the LEVEL-2 trial is ongoing, targeting completion by end-2027. Levosimendan (TNX-103) is being evaluated for pulmonary hypertension associated with heart failure.
07-31 11:00
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
Evercore ISI Group Initiates Coverage On Tenax Therapeutics with Outperform Rating, Announces Price Target of $39
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Outperform rating and announces Price Target of $39.
07-22 22:59
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Tenax Therapeutics, Inc. awarded inducement option awards to three newly hired non-executive employees on July 1, 2026, as material inducements to their employment. The employees received non-qualified stock options to purchase 160,000 shares of the Company's common stock, with 25% vesting on the first anniversary of the grant date and the remaining shares vesting in 36 equal monthly installments. The awards were approved by the Board's Compen...
07-02 20:05
Tenax Therapeutics To Present Results From Phase 3 LEVEL Clinical Trial In Late-Breaking Clinical Science Session At ESC Congress 2026
Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company") announced today t...
07-02 19:03
